

Adenosine and inosine increase cutaneous vasopermeability by activating A₃ receptors on mast cells

Stephen L. Tilley, ... , Marlene A. Jacobson, Beverly H. Koller

J Clin Invest. 2000;105(3):361-367. <https://doi.org/10.1172/JCI8253>.

Article

Adenosine has potent effects on both the cardiovascular and immune systems. Exposure of tissues to adenosine results in increased vascular permeability and extravasation of serum proteins. The mechanism by which adenosine brings about these physiological changes is poorly defined. Using mice deficient in the A₃ adenosine receptor (A₃AR), we show that increases in cutaneous vascular permeability observed after treatment with adenosine or its principal metabolite inosine are mediated through the A₃AR. Adenosine fails to increase vascular permeability in mast cell-deficient mice, suggesting that this tissue response to adenosine is mast cell-dependent. Furthermore, this response is independent of activation of the high-affinity IgE receptor (FcεR1) by antigen, as adenosine is equally effective in mediating these changes in FcεR1 β-chain-deficient mice. Together these results support a model in which adenosine and inosine induce changes in vascular permeability indirectly by activating mast cells, which in turn release vasoactive substances. The demonstration in vivo that adenosine, acting through a specific receptor, can provoke degranulation of this important tissue-based effector cell, independent of antigen activation of the high-affinity IgE receptor, supports an important role for this nucleoside in modifying the inflammatory response.

Find the latest version:

<https://jci.me/8253/pdf>



Adenosine and inosine increase cutaneous vasopermeability by activating A₃ receptors on mast cells

Stephen L. Tilley,¹ Victoria A. Wagoner,¹ Christopher A. Salvatore,² Marlene A. Jacobson,² and Beverly H. Koller¹

¹Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of North Carolina–Chapel Hill, Chapel Hill, North Carolina 27599, USA

²Department of Pharmacology, Merck Research Labs, West Point, Pennsylvania 19486, USA

Address correspondence to: Beverly H. Koller, 7027 Thurston-Bowles Building, University of North Carolina–Chapel Hill, Chapel Hill, North Carolina 27599-7248, USA. Phone: (919) 962-2153; Fax: (919) 966-7524; E-mail: treawouns@aol.com.

Received for publication August 25, 1999, and accepted in revised form December 10, 1999.

Adenosine has potent effects on both the cardiovascular and immune systems. Exposure of tissues to adenosine results in increased vascular permeability and extravasation of serum proteins. The mechanism by which adenosine brings about these physiological changes is poorly defined. Using mice deficient in the A₃ adenosine receptor (A₃AR), we show that increases in cutaneous vascular permeability observed after treatment with adenosine or its principal metabolite inosine are mediated through the A₃AR. Adenosine fails to increase vascular permeability in mast cell-deficient mice, suggesting that this tissue response to adenosine is mast cell-dependent. Furthermore, this response is independent of activation of the high-affinity IgE receptor (FcεR1) by antigen, as adenosine is equally effective in mediating these changes in FcεR1 β-chain-deficient mice. Together these results support a model in which adenosine and inosine induce changes in vascular permeability indirectly by activating mast cells, which in turn release vasoactive substances. The demonstration *in vivo* that adenosine, acting through a specific receptor, can provoke degranulation of this important tissue-based effector cell, independent of antigen activation of the high-affinity IgE receptor, supports an important role for this nucleoside in modifying the inflammatory response.

J. Clin. Invest. 105:361–367 (2000).

Introduction

Adenosine and its primary metabolite inosine are ubiquitous nucleosides that can be released in substantial quantities from ischemic tissue and stimulated mast cells (1–4). Adenosine acts through cell-surface adenosine receptors to orchestrate numerous physiological events in multiple tissues. Few physiological roles have been ascribed to inosine, and only recently has it been shown that inosine can participate in receptor-mediated signaling (5). To date, 4 adenosine receptors have been identified, A₁, A_{2A}, A_{2B}, and A₃, each with unique tissue distributions, ligand affinity, and signal transduction mechanisms (6). A₁ and A_{2A} receptors are activated by submicromolar concentrations of adenosine, whereas A_{2B} and A₃ receptors become activated only when adenosine levels rise into the micromolar range. Inosine has been shown to bind to A₃ receptors in the range of 10–50 μM (5). These differences in ligand affinity have important physiological implications, as tissue levels of adenosine and inosine are believed to increase into the micromolar range during periods of inflammation, hypoxia, or ischemia (1, 3, 4, 7). Hence, the A_{2B} and A₃ receptors have become attractive pharmacologic targets for modifying the inflammatory response.

Changes in microvascular permeability are crucial to the development and perpetuation of the inflammatory response. It has been recognized for many years that

adenosine can produce vasodilatation and increases in capillary permeability in numerous vascular beds (8–11). Although there is evidence that cAMP-coupled A₂ receptors on vascular smooth muscle are responsible for adenosine-mediated vasodilatation (12), the precise mechanism involved and the receptors mediating vascular permeability changes are not as well established (13–15). Furthermore, it is not clear whether adenosine acts directly on endothelial cells, or if the observed increase in vascular permeability is indirect, resulting from mediator release by stimulated immune cells.

A number of lines of evidence suggest that adenosine receptors are present on endothelial cells and that direct activation of these receptors results in alteration of endothelial permeability. Although the permeability of *in vitro* monolayers of macrovascular aortic endothelial cells decreases in response to adenosine, microvascular endothelial cells demonstrate adenosine-induced increases in permeability (16, 17). Several whole-vessel preparations and *in vivo* studies in multiple tissues have shown increases in microvascular permeability after exposure to adenosine; however, these experiments are confounded by adenosine's effects on perivascular immune cells (9–11).

Mast cells are present in most tissues and are often found in close proximity to blood vessels, including capillaries and postcapillary venules (18–20). Upon

stimulation, these cells release a number of mediators, including leukotrienes, histamine, and serotonin, that act directly on the vasculature to produce vasodilatation, increased permeability, and subsequent plasma protein extravasation into surrounding tissue (21). The ability to release these vasoactive substances suggests that the mast cell may play a key role in regulating these physiological processes.

Modulation of mast-cell function by adenosine has been extensively investigated. In vitro studies have shown that adenosine can potentiate mediator release from stimulated mast cells but cannot provoke mediator release alone (22). However, a number of studies suggest that adenosine can initiate mast-cell degranulation in vivo in the absence of additional stimuli (23, 24). Because adenosine fails to initiate degranulation of mast cells in culture, it is not clear that this in vivo response is mediated by binding of adenosine to a particular receptor and, moreover, which of the adenosine receptors found on mast cells is required for this response.

Efforts to define the adenosine receptor responsible for these effects on mast-cell degranulation has been difficult owing to incomplete specificity of receptor agonists and antagonists. Nevertheless, most studies suggest that A_{2B} and A_3 receptors are predominantly involved (24–32). The differential importance assigned to these receptors in mast-cell degranulation may reflect the fact that mast cells examined were from different species and tissues.

To further delineate the mechanisms by which adenosine and its principal metabolite inosine mediate proinflammatory effects on tissues, we examined the vascular response to these nucleosides using 3 mutant mouse lines; namely, mice lacking the A_3 adenosine receptor, mice lacking mast cells, and mice lacking a functional high-affinity receptor for IgE. These animals have enabled us both to define the mechanism by which adenosine induces changes in cutaneous vascular permeability in vivo and to determine the receptor through which adenosine and inosine exert these physiological effects.

Methods

Animal welfare. The use of experimental animals was in accordance with the Institutional Animal Care and Use Committee guidelines of the University of North Carolina at Chapel Hill.

A_3AR -deficient, $Fc\epsilon R1$ β chain-deficient, and mast cell-deficient mice. Gene targeting in murine embryonic stem cells was used to generate mice deficient in the A_3AR and in the β chain of the $Fc\epsilon R1$ high-affinity IgE receptor as described previously (32, 33). Mast cell-deficient mice ($WBB6F_1/J-W/W^v$) and their congenic normal littermates ($WBB6F_1/J-W/W^+$) were purchased from The Jackson Laboratory (Bar Harbor, Maine, USA). Experiments were carried out with $A_3AR^{-/-}$ mice of various ages, ranging from 16 to 98 weeks old. Age-matched littermates were used as $A_3AR^{+/+}$ controls in all experiments. Mast

cell-deficient mice and their controls ranged from 10 to 16 weeks old. $Fc\epsilon R1$ β chain-deficient mice and their controls ranged from 10 to 14 weeks old.

Isolation of bone marrow-derived mast cells. Bone marrow-derived mast cells (BMMCs) were isolated from the femurs of 3- to 6-month-old mice and placed in culture for at least 4 weeks in the presence of murine IL-3 to select for pure populations of mast cells as described previously (34). Culture media consisted of RPMI 1640 medium supplemented with 8% FCS, 8% murine IL-3 culture supplement (Collaborative Biomedical Products, Bedford, Massachusetts, USA), 20 mM HEPES, 4 mM L-glutamine, 0.08 U/mL penicillin, 0.08 U/mL streptomycin, 800 μ M nonessential amino acids, 800 μ M sodium pyruvate, 0.04 mg/mL gentamicin, and 92 μ M β -mercaptoethanol. Cell cultures were maintained at a constant 37°C in a humidified chamber containing 5% CO_2 . Adherent cells (macrophages, monocytes) were depleted from culture by transferring cells in suspension to fresh media weekly at a concentration of 1×10^5 to 5×10^5 cells/mL.

Hexosaminidase assay. Mast cells were incubated overnight at 37°C with monoclonal murine anti-DNP IgE (clone SPE-7; Sigma Chemical Co., St. Louis, Missouri, USA) at a concentration of 100 ng/mL per million cells to give 100% occupancy of IgE receptors. Cells were washed twice with a glucose-saline, Pipes-buffered medium containing 1 mM calcium (Siraganian buffer; also with KCl, $MgCl_2$, BSA [pH 7.2]) and transferred to 96-well microtiter plates at a concentration of 500,000 cells per 75 μ L. Cells were incubated with or without adenosine for 1 minute before stimulation with antigen (DNP-albumin, 10 ng/mL; Sigma Chemical Co.). Reactions were terminated after 20 minutes by centrifuging samples at 4°C at 2,000 g for 5 minutes. Hexosaminidase secretion was determined by incubating supernatant and cell lysate with 1 mM *p*-nitrophenyl-*N*-acetyl- β -D-glucosaminide (*p*-NAG, molecular weight 342.3; Sigma Chemical Co.). After a 1-hour incubation at 37°C, 0.1 M $Na_2CO_3/NaHCO_3$ was added and absorbance was read at 405 nm. Hexosaminidase release was expressed as a percentage of the total amount of hexosaminidase present in the cells.

Intradermal adenosine and inosine. Mice were injected with 100 μ L of 1% Evans blue (Sigma Chemical Co.) in PBS intravenously by tail vein. One hour later, they were anesthetized and given 20 μ L of adenosine (10^{-3} – 10^{-4} M) or inosine (10^{-4} M) and 20 μ L of PBS into the right and left ears, respectively. One hour after intradermal injections, mice were sacrificed by cervical dislocation, and 7-mm ear punches were obtained from each ear. The Evans blue dye was extracted by incubation in 0.5 mL of formamide at 55°C for 48 hours and was quantitated by measuring the absorbance of Evans blue at 610 nm with a spectrophotometer (35).

Histological analysis. Organs were harvested from $A_3AR^{+/+}$ and $A_3AR^{-/-}$ mice and fixed in 10% formalin. Tissue was embedded in paraffin, and 5- μ m sections were cut and stained with toluidine blue. Mast-cell

Table 1

Number of mast cells per square millimeter

Organ	$A_3AR^{+/+}$	$A_3AR^{-/-}$
Ear	106.8 ± 4.0	102.2 ± 8.6
Skin	11.2 ± 3.3	11.2 ± 1.4
Tongue	8.0 ± 0.1	8.2 ± 0.7
Trachea	5.4 ± 0.4	4.3 ± 1.2
Stomach	5.0 ± 0.6	4.4 ± 0.4

numbers in each tissue were quantitated in a blinded fashion by counting the number of positively staining cells in each tissue from 3 animals of each genotype.

Passive cutaneous anaphylaxis. Passive cutaneous anaphylaxis was performed as described previously (36). Briefly, animals were lightly anesthetized and injected intradermally in the right ear with 20 ng of murine monoclonal anti-DNP IgE diluted in 20 μ L of PBS. The left ear was injected with PBS alone. Twenty-four hours later, the animals were injected intravenously with 100 μ g of DNP-albumin in 100 μ L of 0.9% PBS; 1% Evans blue dye was added to permit visual localization of increased vascular permeability. The reaction was quantitated at 90 minutes after injection as already described here.

Passive systemic anaphylaxis. Passive systemic anaphylaxis was performed as described previously (37). Briefly, animals were injected intravenously with 200 μ L of PBS containing 20 μ g of a murine monoclonal anti-DNP IgE, and 24 hours later, with 200 μ L of PBS containing 1% Evans blue dye and 1 mg DNP-albumin. Control animals received antigen only or IgE only. Baseline temperature was established for each animal using a rectal probe before injection of the antigen. Temperature drops due to anaphylactic response were recorded at 20, 30, 40, and 50 minutes after the injection of antigen. Ear edema was quantitated as already described here.

Statistical analysis. Data are presented as mean \pm SEM. Statistical significance was assessed by using the unpaired Student's *t* test.

Results

Effect of adenosine and inosine on degranulation of BMMCs. To compare the effect of adenosine and its metabolite inosine on mast-cell function, in particular mast-cell degranulation, BMMCs were prepared from wild-type and $A_3AR^{-/-}$ mice. Wild-type and $A_3AR^{-/-}$ BMMCs were exposed to increasing concentrations of either adenosine or inosine, and degranulation was assessed by measuring the release of hexosaminidase, an enzyme present in mast-cell granules. No increase in hexosaminidase was seen upon exposure of up to 100 μ M adenosine or inosine, indicating that neither nucleoside alone provoked degranulation of BMMCs. To compare the ability of these 2 agents to potentiate antigen-mediated BMMC degranulation, mast cells were loaded with IgE and subsequently exposed to antigen and various concentrations of adenosine and inosine. IgE-dependent degranulation without adenosine or inosine was

similar between genotypes ($27 \pm 3\%$ vs. $27 \pm 5\%$). As shown in Figure 1, adenosine and inosine both enhanced antigen-mediated degranulation of wild-type mast cells. However, a maximum increase in potentiation of this response by adenosine was seen at concentrations approximately 10-fold lower than that seen with inosine. At a dose of 100 μ M, inosine increased hexosaminidase release by $34 \pm 4\%$ ($P = 0.008$), whereas adenosine enhanced release by $67.3 \pm 11\%$ ($P = 0.028$). To determine whether inosine mediates its action through one of the adenosine receptors, we examined the ability of inosine to potentiate degranulation of $A_3AR^{-/-}$ mast cells. Similar to adenosine, inosine failed to potentiate antigen-induced degranulation in BMMCs from $A_3AR^{-/-}$ mice (Figure 1). Antigen-induced degranulation in $A_3AR^{-/-}$ cells could, however, be potentiated by other secretagogues such as PGE₂ to similar extents as that seen in BMMCs from wild-type animals ($26 \pm 6\%$ release with antigen; $53 \pm 2\%$ release with antigen and PGE₂). These results indicate that the ability of both adenosine and inosine to enhance antigen-induced degranulation of murine BMMCs occurs exclusively through activation of the A₃ adenosine receptor.

Changes in vascular permeability in response to adenosine and inosine in $A_3AR^{+/+}$ and $A_3AR^{-/-}$ mice. We examined the effects of adenosine and inosine on microvascular permeability and plasma protein extravasation in the skin by intradermally injecting these nucleosides into the pinna of the mouse ear. Evans blue dye binds to serum proteins and remains confined to the intravascular space unless vascular permeability is altered. Quantitation of the dye present in the ear can therefore be used to quantify the levels of plasma protein extravasation into tissue. As shown in Figure 2a, intradermal adenosine caused significant extravasation of plasma proteins into the ears of $A_3AR^{+/+}$ mice. Inosine was also effective at producing protein extravasation. However, in contrast to our *in vitro* data, inosine was at least as effective as adenosine in producing this response. To determine whether these effects were mediated through a specific receptor, we measured the ability of these agents to cause plasma protein extravasation in $A_3AR^{-/-}$ mice. Neither adenosine nor inosine evoked dye extravasation in any of the $A_3AR^{-/-}$ animals tested, even at concentrations as high as 1 mM (Figure 2a).

Adenosine-induced edema in mast cell-deficient mice. To determine whether the plasma protein extravasation in response to adenosine was due to direct effects on the endothelium or secondary to mast cell-mediator release, adenosine was delivered intradermally into the pinna of the ears of mast cell-deficient mice and their wild-type littermate controls. Although edema formation was seen in the wild-type animals, it was not observed in the mast cell-deficient mice (Figure 2b). These findings suggest that A₃AR activation of mast cells is the physiological mechanism behind adenosine-induced changes in vascular permeability.

Mast-cell histology. To verify that the absence of the A₃ receptor did not affect mast-cell development, mast cells




Figure 1 Potentiation of antigen-induced degranulation of BMMCs from $A_3AR^{-/-}$ and $A_3AR^{+/+}$ mice by adenosine and inosine. IgE-loaded mast cells were incubated with antigen (DNP-albumin) in the presence or absence of increasing concentrations of adenosine or inosine. The amount of degranulation was determined by measuring the percent hexosaminidase released from cells. Data represent the mean percent increase in hexosaminidase release with adenosine and inosine, \pm SEM from 3 experiments, each performed in duplicate. Ado = adenosine, Ino = inosine. * $P < 0.03$.

were examined from $A_3AR^{-/-}$ animals and controls. Morphologically, BMMCs isolated from $A_3AR^{-/-}$ mice were indistinguishable from those obtained from $A_3AR^{+/+}$ animals. Tissue mast cells stained with toluidine blue also appeared morphologically similar between genotypes. Table 1 summarizes the number of resident mast cells present in various tissues from $A_3AR^{-/-}$ and $A_3AR^{+/+}$ mice. No differences in cell numbers were found between genotypes in any of the tissues examined. Quantification of mast cells in the stomach was based on counting mast cells in the submucosa and muscularis propria and did not include mucosal mast cells.

Passive cutaneous and systemic anaphylaxis. Previous work has demonstrated that increases in plasma protein extravasation seen during a passive anaphylaxis response in the mouse results from activation of mast cells by antigen and IgE via the Fc ϵ R1 receptor (37). Therefore, to determine whether tissue mast cells of the $A_3AR^{-/-}$ animals could respond to other stimuli and whether the magnitude of this response was altered as a result of loss of the A_3AR , we examined plasma protein extravasation after the induction of passive cutaneous and systemic anaphylaxis. The cutaneous anaphylactic response was elicited by loading mast cells intradermally with murine monoclonal IgE specific for DNP-albumin. Twenty-four hours later, the antigen was administered intravenously. Similar to $A_3AR^{+/+}$ mice, intravenously administered antigen led to localized plasma protein extravasation at the site of intradermal IgE administration in $A_3AR^{-/-}$ animals (data not shown). While many of the $A_3AR^{-/-}$ mice displayed a slightly blunted response, the observed differences between genotypes were not statistically significant ($P = 0.21$).

A systemic anaphylactic response was elicited in wild-type and $A_3AR^{-/-}$ mice by intravenously loading tissue mast cells with monoclonal IgE specific for DNP-albumin. Twenty-four hours later, the DNP antigen was administered intravenously. In wild-type mice, passive systemic anaphylaxis is characterized by profound shock with hypotension, hypothermia, and increased vascular permeability leading to generalized fluid extravasation. We quantified the anaphylactic response in 2 ways. First, temperature change was monitored rectally at various times after administration of antigen; and second, changes in vascular permeability were determined by measuring Evans blue dye extravasation into ear tissue. Antigen administration resulted in progressive hypothermia in both wild-type and $A_3AR^{-/-}$ animals over the time interval measured (data not shown). The body temperature dropped significantly in the animals that received IgE and antigen compared with control animals treated with either IgE alone or antigen alone ($P < 0.05$). No significant differences were detected between genotypes at any time point measured. Vascular permeability also increased in both wild-type and $A_3AR^{-/-}$ animals after antigen challenge (data not shown). Again, no significant differences were observed between genotypes ($P = 0.31$).

Adenosine-mediated edema formation in Fc ϵ R1-deficient mice. It is possible that the ability of adenosine to initiate degranulation of tissue mast cells, but not BMMCs, is dependent on occupancy, in vivo, of the high-affinity IgE receptor, Fc ϵ R1, with subthreshold levels of IgE and antigen. To test this hypothesis, the response of mice lacking the β chain of the Fc ϵ R1 receptor to adenosine was examined. It has been shown previously that expression of functional Fc ϵ R1 in murine mast cells is dependent on the expression of the β chain (33). As shown in Figure 2b, a similar degree of plasma protein extravasation was seen in wild-type and Fc ϵ R1-deficient animals in response to adenosine ($P = 0.84$). These results suggest that mast-cell activation by adenosine in vivo occurs independent of any Fc ϵ R1 receptor-mediated signal transduction.

Discussion

Adenosine and inosine can have dramatic effects on vascular permeability, with edema formation occurring rapidly upon cutaneous exposure to these nucleosides. We show here that these physiological changes are mediated through the binding of adenosine and inosine to the A_3 adenosine receptor. Lack of plasma protein extravasation after the intradermal administration of adenosine in mast cell-deficient mice fails to support a model in which adenosine induces changes in vascular permeability by acting directly on adenosine receptors expressed by endothelial cells. Rather, these findings are consistent with the hypothesis that adenosine and inosine mediate changes in vascular permeability indirectly by activation of tissue mast cells, which in turn release secondary mediators that act on endothelial cells. The experiments described here also

show that adenosine and inosine alone can provide, through activation of the A_3 receptor, sufficient signal for degranulation of intradermal mast cells *in vivo*. These findings contrast with *in vitro* studies using BMMCs, in which exposure to adenosine or inosine alone does not result in mast-cell degranulation.

Previous work has shown that adenosine can influence vascular permeability in multiple tissues, and our results showing edema formation in the mouse after the intradermal injection of adenosine are consistent with these studies (9–11, 17). It has previously been difficult to definitively assign a specific adenosine receptor to a given physiological response owing to the incomplete selectivity of adenosine receptor agonists and antagonists. Our studies show that plasma protein extravasation in response to adenosine is mediated entirely through activation of the A_3 receptor, as adenosine cannot provoke this physiological response in mice lacking this receptor. These findings are consistent with reports showing that pharmacologic reagents that preferentially bind to the A_3 receptor are effective at inducing edema formation (30, 38).

To determine whether adenosine-mediated increases in cutaneous vasopermeability are due to direct effects on the vasculature or occur indirectly through mast cell–mediator release, we used mast cell–deficient mice and their congenic littermate controls. Control mice showed the expected increase in vascular permeability in response to adenosine, whereas mast cell–deficient mice showed no response. These results suggest that mast cells are required for the induction of plasma protein extravasation by adenosine and that adenosine does not act directly on the vasculature to produce these physiological changes. Earlier *in vitro* studies using microvascular endothelial cells have shown adenosine to have direct effects on permeability (17). It is possible that these discrepancies reflect a difference in the site and cell type exposed to adenosine. In the experiments described here, adenosine was delivered to the interstitial space. It is possible that high levels of adenosine delivered to the luminal surface of the endothelial cell may directly alter postcapillary permeability. *In vivo* studies have also suggested that adenosine may have direct effects on the vasculature; however, the results of most of these studies are confounded by the presence of perivascular mast cells (9, 10). Recently, studies of vascular permeability in the skin of conscious rats after exposure to adenosine analogues have suggested an indirect action through mediator release from mast cells, as plasma protein extravasation after the intradermal administration of an adenosine analogue was nearly eliminated when animals were pre-treated with either a histamine and serotonin antagonist or compound 48/80 that depletes mast-cell mediators (30). Our results are in agreement with these observations and provide evidence that adenosine's effects on cutaneous vascular permeability are mast-cell mediated. Formal proof that these effects are indeed mast-cell mediated awaits successful and unsuccessful




Figure 2

Plasma protein extravasation after intradermal adenosine and inosine in wild-type (+/+), A_3AR -deficient ($A_3AR^{-/-}$), mast cell-deficient (W/W^v), and $Fc\epsilon R1$ β -chain-deficient mice ($Fc\epsilon R1^{-/-}$). Mice were injected intravenously with 100 μ L of 1% Evans blue in PBS. One hour later, 20 μ L of adenosine 10^{-3} M or inosine 10^{-4} M (a), or adenosine 10^{-4} M (b), was injected intradermally into the right ear of each animal. Control ears (left ears) were injected with 20 μ L of PBS. One hour after intradermal injections, 7-mm ear biopsies were obtained and placed in formamide at 57°C for 48 hours to extract dye. Plasma protein extravasation was quantitated by measuring OD at 610 nm. Data represent the mean difference in OD between PBS-treated ears and nucleoside-treated ears, \pm SEM. n = number of animals in each group. * P < 0.005.

restoration of the response to adenosine in mast cell–deficient mice reconstituted with $A_3AR^{+/+}$ and $A_3AR^{-/-}$ BMMCs, respectively.

Given our findings that the edema response to adenosine is mast cell–dependent, and that this response is absent in the A_3AR -deficient mice, 2 possible explanations need to be considered. One possibility is that the failure to see a response in the A_3AR -deficient mice is due to the nonresponsiveness of mast cell to adenosine because of the absence of A_3AR receptor expression. An alternative hypothesis is that the A_3AR plays an important role in the development, migration, or overall survival of mast cells and that loss of this receptor renders mice mast-cell deficient. Two lines of experimental data support the former hypothesis. First, mast cells were found in approximately normal numbers in all tissues examined and could not be distinguished from wild-type controls based on morphological criteria. Perhaps more convincing data supporting the normal development of mast cells in $A_3AR^{-/-}$ mice are the demonstration that loss of this receptor has

only a minimal impact on systemic and cutaneous IgE-mediated anaphylaxis in these animals. A small decrease in response to cutaneous anaphylaxis was observed, but this difference did not reach statistical significance. It is possible that this trend may be related to the *in vitro* demonstration that adenosine, acting through the A₃ receptor, potentiates IgE-mediated mast-cell degranulation. The role of adenosine in this response may be difficult to measure when mast cells are maximally stimulated in passive anaphylaxis, and further studies with suboptimal doses of antigen or antibody may reveal a greater role for adenosine in these mast cell-mediated inflammatory responses. Moreover, further insight into the contribution of adenosine to disease processes such as asthma, in which mast-cell activation is believed to play a role, may be gained by examining A₃AR-deficient mice in established models of this disease.

Previous investigations using murine BMMCs have shown adenosine's potentiation of degranulation in these cells to be partially pertussis-toxin sensitive (39). These same investigators also showed that adenosine-mediated rises in inositol trisphosphate (IP₃) and intracellular calcium were pertussis-toxin insensitive (39). Because A₃-mediated signal transduction has been shown to be sensitive to pertussis toxin (40, 41), it has been speculated that another adenosine receptor, such as the A_{2B} receptor, plays a role in adenosine's actions on BMMC degranulation. Our results showing the potentiation of antigen-stimulated BMMC degranulation by adenosine through the A₃ receptor do not support these observations. A₃ receptors have been shown to interact with multiple G proteins including G_i and G_q, and it has been suggested that A₃AR stimulation of phospholipase C may have a pertussin toxin-insensitive component in some systems (42).

While adenosine can potentiate antigen-induced mast-cell degranulation *in vitro*, it cannot initiate degranulation independent of an additional stimulus. In contrast, adenosine alone appears to be sufficient to activate mast cells *in vivo*. Studies carried out in several species support this observation (23, 24, 29–31). Several different hypotheses can explain the profound effect of adenosine on mast-cell function *in vivo*. First, BMMCs in tissue culture may be immature and lack the necessary signaling mechanisms required to initiate degranulation in response to adenosine. Second, the ability of adenosine to initiate degranulation may vary between different mast-cell types. Tissue mast cells can be classified into either connective tissue or mucosal mast cells based on certain morphological and histochemical characteristics, and it has been suggested that BMMCs more closely resemble the latter (21). The *in vivo* studies described here examine the cutaneous response to adenosine and, therefore, reflect activation of A₃AR on connective tissue mast cells. Finally, *in vivo*, low levels of antigen may be bound to IgE receptors occupied by circulating IgE, providing the additional signaling necessary for acti-

vation of mast cells by adenosine. The availability of mouse lines lacking a functional FcεR1 receptor has enabled us to test this hypothesis directly. Intradermal administration of adenosine to these mice results in a similar degree of plasma protein extravasation as observed in wild-type controls, establishing that adenosine-induced mast-cell degranulation *in vivo* occurs independently of the presence of signal transduction by the high affinity IgE receptor.

Although it is well accepted that adenosine is a paracrine and autocrine mediator in a broad spectrum of physiological responses, less information is available concerning the functions of inosine, a primary metabolite of adenosine. Two different routes for metabolism of adenosine have been described. First, adenosine can be used as a substrate for nucleotide synthesis producing ADP and ATP, which themselves have potent receptor-mediated biologic reactions (43). Alternatively, adenosine can be converted by adenosine deaminase to inosine. The activity of these 2 pathways is believed to be regulated, at least in part, by the substrate availability (44). When levels of adenosine are low, most adenosine is converted to AMP by adenosine kinase. However, when adenosine levels increase as a result of trauma, shock, exercise, hypoxia, or endotoxin, adenosine deamination predominates, leading to significant increases in inosine production and resultant interstitial levels of inosine that can rise to greater than 1 mM (44, 45). The biologic significance of these high tissue levels of inosine has not been established, nor is it known whether this metabolite mediates its actions solely by binding to adenosine receptors or whether it mediates its effects through yet undescribed inosine receptors. *In vitro* studies have shown that inosine can potentiate antigen-induced degranulation of both rat serosal mast cells and rat RBL-2H3 mastlike cells (5, 46). We show here that inosine can also potentiate the degranulation of BMMCs. Furthermore, this response is not seen in A₃AR-deficient mast cells, demonstrating that inosine's actions on BMMCs are mediated through the A₃ receptor. These findings are consistent with recent pharmacologic studies that showed inosine to preferentially bind to recombinant rat A₃ receptors (5). These studies also suggest that adenosine is more effective than inosine in mediating this response and are consistent with earlier studies with rat mast cells that showed inosine to be some 10 times less potent than adenosine at enhancing antigen-induced degranulation (46).

Intradermal injection of inosine was at least as effective as adenosine at eliciting an edema response. This finding is consistent with pharmacologic studies that suggested that inosine can activate the A₃ receptor (5). Thus, the studies reported here support a physiological role for inosine in the acute inflammatory response and show that these effects of inosine are mediated solely through an adenosine receptor, specifically the A₃ receptor. This does not rule out the possibility that other biologic responses of inosine may be mediated by other adenosine receptors or yet uncharacterized receptors.

In summary, we have shown that both adenosine and its principal metabolite inosine promote plasma protein extravasation through activation of A₃ adenosine receptors. Lack of any changes in vascular permeability in mast cell-deficient mice after exposure to adenosine suggests that adenosine acts indirectly through A₃ receptors on mast cells to produce these physiological changes. These actions of adenosine in vivo occur independently of the presence of the expression of the high-affinity IgE receptor, suggesting a more profound role for adenosine as a modifier of the inflammatory response.

Acknowledgments

The authors thank S. Galli and C. Williams for helpful advice, and M. Solle for critical review of the manuscript. This work was supported by an American Lung Association Research Training Fellowship Award (S.L. Tilley) and a grant from the National Institutes of Health (HL58554 to B.H. Koller).

- Mentzer, R.M., Rubio, R., and Berne, R.M. 1975. Release of adenosine by hypoxic canine lung tissue and its possible role in pulmonary circulation. *Am. J. Physiol.* **229**:1625–1631.
- Marquardt, D.L., Gruber, H.E., and Wasserman, S.I. 1984. Adenosine release from stimulated mast cells. *Proc. Natl. Acad. Sci. USA.* **81**:6192–6196.
- Schrader, J., and Gerlach, E. 1976. Compartmentation of cardiac adenine nucleotides and formation of adenosine. *Pflugers Arch.* **367**:129–135.
- Rubio, R., Berne, R.M., Bockman, E.L., and Curnish, R.R. 1975. Relationship between adenosine concentration and oxygen supply in rat brain. *Am. J. Physiol.* **228**:1896–1902.
- Jin, X., Shepherd, R.K., Duling, B.R., and Linden, J. 1997. Inosine binds to A₃ adenosine receptors and stimulates mast cell degranulation. *J. Clin. Invest.* **100**:2849–2857.
- Ralevic, V., and Burnstock, G. 1998. Receptors for purines and pyrimidines. *Pharmacol. Rev.* **50**:413–492.
- Mills, G.C., Schmalstieg, F.C., Trimmer, K.B., Goldman, A.S., and Goldblum, R.M. 1976. Purine metabolism in adenosine deaminase deficiency. *Proc. Natl. Acad. Sci. USA.* **73**:2867–2871.
- Collis, M.G. 1989. The vasodilator role of adenosine. *Pharmacol. Ther.* **41**:143–162.
- Gawlowski, D.M., and Duran, W.N. 1986. Dose-related effects of adenosine and bradykinin on microvascular permeability to macromolecules in the hamster cheek pouch. *Circ. Res.* **58**:348–355.
- Overholser, K.A., and Harris, T.R. 1984. Effect of exogenous adenosine on resistance, capillary permeability-surface area and flow in ischemic canine myocardium. *J. Pharmacol. Exp. Ther.* **229**:148–152.
- Sollevi, A., and Fredholm, B. 1981. Role of adenosine in adipose tissue circulation. *Acta Physiol. Scand.* **112**:293–298.
- Wiener, H.L., and Thalody, G.P. 1993. Kinetic characterization of adenosine A₂ receptor-mediated relaxation in isolated rabbit aorta. *Eur. J. Pharmacol.* **238**:65–74.
- Abiru, T., Endo, K., and Machida, H. 1995. Differential vasodilatory action of 2-octynyladenosine (YT-146), an adenosine A₂ receptor agonist, in the isolated rat femoral artery and vein. *Eur. J. Pharmacol.* **281**:9–15.
- Haynes, J., Jr., Obiako, B., Thompson, W.J., and Downey, J. 1995. Adenosine-induced vasodilation: receptor characterization in pulmonary circulation. *Am. J. Physiol.* **268**:H1862–H1868.
- Elliott, J., and Brady, F.E. 1998. Characterization of vasodilatory adenosine receptors in equine digital veins. *J. Vet. Pharmacol. Ther.* **21**:74–81.
- Haselton, F.R., Alexander, J.S., and Mueller, S.N. 1993. Adenosine decreases permeability of in vitro endothelial monolayers. *J. Appl. Physiol.* **74**:1581–1590.
- Watanabe, H., Kuhne, W., Schwartz, P., and Piper, H.M. 1992. A₂-adenosine receptor stimulation increases macromolecule permeability of coronary endothelial cells. *Am. J. Physiol.* **262**:H1174–H1181.
- Galli, S.J. 1990. New insights into “the riddle of the mast cells”: microenvironmental regulation of mast cell development and phenotypic heterogeneity. *Lab. Invest.* **62**:5–33.
- Rakusan, K., Sarkar, K., Turek, Z., and Wicker, P. 1990. Mast cells in the rat heart during normal growth and in cardiac hypertrophy. *Circ. Res.* **66**:511–516.
- Rhodin, J.A.G., and Fujita, H. 1989. Capillary growth in the mesentery of normal young rats. Intravital video and electron microscope analyses. *J. Submicrosc. Cytol. Pathol.* **21**:1–34.
- Metcalfe, D.D., Baram, D., and Mekori, Y.A. 1997. Mast cells. *Physiol. Rev.* **77**:1033–1079.
- Marquardt, D.L., Parker, C.W., and Sullivan, T.J. 1978. Potentiation of mast cell mediator release by adenosine. *J. Immunol.* **120**:871–878.
- Doyle, M.P., Linden, J., and Duling, B.R. 1994. Nucleoside-induced arteriolar constriction: a mast cell-dependent response. *Am. J. Physiol.* **266**:H2042–H2050.
- Hannon, J.P., Pfannkuche, H.J., and Fozard, J.R. 1995. A role for mast cells in adenosine A₃ receptor-mediated hypotension in the rat. *Br. J. Pharmacol.* **115**:945–952.
- Marquardt, D.L., Walker, L.L., and Heinemann, S.F. 1994. Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells. *J. Immunol.* **150**:4508–4515.
- Feoktistov, I., and Biaggioni, I. 1995. Adenosine A_{2b} receptors evoke interleukin-8 secretion in human mast cells. *J. Clin. Invest.* **96**:1979–1986.
- Auchampach, J.A., Jin, X., Wan, T.C., Caughey, G.H., and Linden, J. 1997. Canine mast cell adenosine receptors: cloning and expression of the A₃ receptor and evidence that degranulation is mediated by the A_{2b} receptor. *Mol. Pharmacol.* **52**:846–860.
- Ramkumar, V., Stiles, G.L., Beaven, M.A., and Ali, H. 1993. The A₃ adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. *J. Biol. Chem.* **268**:16887–16890.
- Fozard, J.R., Pfannkuche, H.J., and Schuurman, H.J. 1996. Mast cell degranulation following adenosine A₃ receptor activation in rats. *Eur. J. Pharmacol.* **298**:293–297.
- Reeves, J.J., Jones, C.A., Sheehan, M.J., Vardey, C.J., and Whelan, C.J. 1997. Adenosine A₃ receptors promote degranulation of rat mast cells both in vitro and in vivo. *Inflamm. Res.* **46**:180–184.
- Shepherd, R.K., Linden, J., and Duling, B.R. 1996. Adenosine-induced mast vasoconstriction in vivo. *Circ. Res.* **78**:627–634.
- Salvatore, C.A., et al. Disruption of the A₃ adenosine receptor gene in mice and its effect on stimulated inflammatory cells. *J. Biol. Chem.* In press.
- Dombrowicz, D., et al. 1998. Allergy-associated Fc ϵ R β is a molecular amplifier of IgE- and IgG-mediated in vivo responses. *Immunity.* **8**:517–529.
- Rottem, M., Barbieri, S., Kinet, J.-P., and Metcalfe, D.D. 1992. Kinetics of the appearance of Fc ϵ RI-bearing cells in interleukin-3-dependent mouse bone marrow cultures: correlation with histamine content and mast cell maturation. *Blood.* **79**:972–980.
- Jancso-Gabor, A., Szolcsanyi, J., and Jancso, N. 1967. A simple method for measuring the amount of azovan blue exuded into the skin in response to an inflammatory stimulus. *J. Pharm. Pharmacol.* **19**:486–487.
- Takai, T., Li, M., Sylvestre, D., Clynes, R., and Ravetch, J.V. 1994. Fc γ chain deletion results in pleiotropic effector cell defects. *Cell.* **76**:519–529.
- Dombrowicz, D., Flamand, V., Brigman, K.K., Koller, B.H., and Kinet, J.P. 1993. Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor α chain gene. *Cell.* **75**:969–976.
- Yamawaki, I., Tamaoki, J., Takeda, Y., and Nagai, A. 1998. Effect of adenosine and its analogues on microvascular leakage in the rat trachea. *Nihon Kokyukai Gakkaishi.* **36**:231–235.
- Marquardt, D.L., and Walker, L.L. 1988. Alteration of mast cell responsiveness to adenosine by pertussis toxin. *Biochem. Pharmacol.* **37**:4019–4025.
- Ali, H., Cunha-Melo, J.R., Saul, W.F., and Beaven, M.A. 1990. Activation of phospholipase c via adenosine receptors provides synergistic signals for secretion in antigen-stimulated RBL-2H3 cells. *J. Biol. Chem.* **265**:745–753.
- Linden, J., Thai, T., Figler, H., Jin, X., and Robeva, A.S. 1999. Characterization of human A_{2b} adenosine receptors: radioligand binding, Western blotting, and coupling to G_i in human embryonic kidney 293 cells and HMC-1 mast cells. *Mol. Pharmacol.* **56**:705–713.
- Palmer, T.M., Gettys, T.W., and Stiles, G.L. 1995. Differential interaction with and regulation of multiple G-proteins by the rat A₃ adenosine receptor. *J. Biol. Chem.* **270**:16895–16902.
- Silverman, E.S., Gerritsen, M.E., and Collins, T. 1997. Metabolic functions of the pulmonary endothelium. In *The lung: scientific foundations*. R.G. Crystal, J.B. West, E.R. Weibel, and P.J. Barnes, editors. Lippincott-Raven. Philadelphia, PA. 629–651.
- Hellewell, P.G., and Pearson, J.D. 1983. Metabolism of circulating adenosine by the porcine isolated perfused lung. *Circ. Res.* **53**:1–7.
- Jones, C.E., Thomas, J.X., Devous, M.D., Norris, C.P., and Smith, E.E. 1977. Positive inotropic response to inosine in the in situ canine heart. *Am. J. Physiol.* **233**:H438–H443.
- Church, M.K., Hughes, P.J., and Vardey, C.J. 1986. Studies on the receptor mediating cyclic AMP-independent enhancement by adenosine of IgE-dependent mediator release from rat mast cells. *Br. J. Pharmacol.* **87**:233–242.